Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
about
Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver DiseaseEpidemiology of the metabolic syndrome in the USALeptin induces nitric oxide-mediated inhibition of lipolysis and glyceroneogenesis in rat white adipose tissueGlutathione deficiency down-regulates hepatic lipogenesis in rats.Multifeature analysis of an ultrasound quantitative diagnostic index for classifying nonalcoholic fatty liver disease.Epidemilogical trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease, diabetes mellitus, and non-alcoholic steatohepatitis.Prevalence and sonographic changes compatible with fatty liver disease in patients referred for abdominal ultrasound examination in Aracaju, SE.Ceramide-mediated insulin resistance and impairment of cognitive-motor functionsNitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's diseaseNitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment.The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysisMetabolic Syndrome and Serum Liver Enzymes Level at Patients with Type 2 Diabetes Mellitus.Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.3.0T ¹H magnetic resonance spectroscopy for assessment of steatosis in patients with chronic hepatitis C.Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study.The impact of breakfast in metabolic and digestive health.Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease.Regulation of hepatic gene expression by saturated fatty acids.Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF ratsHepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitisManagement of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Immuno-modulator metallo-Peptide reduces inflammatory state in obese zucker fa/fa ratsFibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosisHIV protease inhibitors in gut barrier dysfunction and liver injury.Treating NAFLD in OLETF rats with vigorous-intensity interval exercise trainingAlpha-lipoic acid reduces LDL-particle number and PCSK9 concentrations in high-fat fed obese Zucker rats.Centrizonal arteries and microvessels in nonalcoholic steatohepatitis.Chronic NOS inhibition accelerates NAFLD progression in an obese rat model.Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease.The effect of cocoa supplementation on hepatic steatosis, reactive oxygen species and LFABP in a rat model of NASHCirculating and dietary trans fatty acids and incident type 2 diabetes in older adults: the Cardiovascular Health Study.Matrix γ-carboxyglutamate protein and Fetuin-A, in wet type age-related macular degenerationWestern diet-induced hepatic steatosis and alterations in the liver transcriptome in adult Brown-Norway rats.Obesity and colorectal cancer.Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.Relation of Anthropometric Obesity and Computed Tomography Measured Nonalcoholic Fatty Liver Disease (from the Multiethnic Study of Atherosclerosis).Mechanisms of ceramide-mediated neurodegeneration.Brain metabolic dysfunction at the core of Alzheimer's disease.Evaluation of relationship between grading of fatty liver and severity of atherosclerotic finding.
P2860
Q26778020-BABBDCE0-E919-4170-97D9-EEA2EE8EC403Q28298801-CCC3369F-F30B-430E-B31F-0C0866DC7B54Q28574330-02B3FEE6-48F0-4878-A6E2-4EE9857BE290Q30318687-7DB9DE74-39D5-4897-92B3-E6E478B5CDA3Q30371936-32F01812-D420-475B-B237-B72995CA94DAQ30376120-0E9D781C-3E22-470B-980B-6B9FB21AD67EQ30390099-9DC14670-3453-49C7-958C-8FA173AE8770Q30478907-D94091D7-A5F1-465B-80D9-F62705C85050Q30479198-1EAF0292-CFDA-4CF7-B83F-DD0AFA87DD4CQ30484122-3290B783-2C4F-40CD-88CD-52DAC4FF2D69Q30497534-A1CCF1E9-402F-47FD-94AE-2A3C4E22649AQ30570152-2216D5F7-AF32-4780-9B09-1D2554609F82Q30572017-56F26837-CC3F-4D90-AA1B-05D0E8EC3D7DQ30971762-80A5FF0C-C348-4638-8757-DC28896F3325Q33573424-DD27B949-883A-4948-846A-0478DACE0129Q33596263-3905D576-7029-49E3-9794-2A27767AB7E8Q33652021-8F09B118-12E9-4760-92D7-915EF5B42474Q33816670-C1D985C7-2FCB-44DB-85F2-B4C53017F1B2Q33836877-BF51AA3B-A24E-40E9-8607-2B62E09D9F5DQ33900501-5CE13A14-96D1-467D-B3F5-3A559839CA70Q33944689-BE6C1BB3-A372-4033-B6F7-DD83DA1DB898Q34168532-102F6B16-BB1E-415A-87BE-C95E98B148D5Q34344972-1700A334-68B1-4FE4-ACCA-4F716AC45B2BQ34396839-9400D434-AD72-4AA7-97B7-47B8089AA220Q34617496-6EA36641-ECB3-4179-99DA-8D863BFCFD56Q34791448-E7281C33-E9F4-47B4-B7F4-F01F4D6C72DEQ35111400-AC889893-A8BD-421B-BE02-4C34B3308DE9Q35165370-C9692CA4-2F1C-4B86-929B-61C4D7EB804CQ35178651-C379FBF8-E355-4723-8CF1-4EC3B8B5E705Q35560585-70F6D59B-3ADB-45BE-8AA6-7A9DB8BE5B5EQ35582682-6B838189-A0A1-4437-A639-5D88C78F3CDBQ35630715-97220A41-93C0-4B70-9F9D-7CE91F2FFAD6Q35691938-D8CCED31-FA30-443C-89E5-50E0ED99732AQ35828088-A4C14864-1F9B-4A80-A6CB-6FAC47CF7D70Q35850154-271A99CE-01D5-46C9-9592-8E076E23C647Q35876759-5A6845C7-469B-4106-916C-23BD86CAB8B3Q35908454-050FBE69-D0CB-468F-84BA-E057FB48C70EQ35997878-CE511627-1809-4B04-AFFA-783B8A383517Q35997881-9EED8B91-9E58-4B26-AB3F-B517528567BFQ36111640-0D3E4B0E-1939-4AD5-B1DC-F96FB4EAE084
P2860
Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
@en
Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
@nl
type
label
Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
@en
Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
@nl
prefLabel
Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
@en
Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
@nl
P2093
P2860
P356
P1476
Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
@en
P2093
Jamal A Ibdah
John P Thyfault
R Scott Rector
Yongzhong Wei
P2860
P304
P356
10.3748/WJG.14.185
P407
P577
2008-01-01T00:00:00Z